Prioritizing targets for precision cancer medicine von Andre, F., Mardis, E., Salm, M., Soria, J.-C., Siu, L.L., Swanton, C.

Volltext

Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription von Brana, I, Siu, L L

Volltext

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly target... von Chau, N.G., Hotte, S.J., Chen, E.X., Chin, S.F., Turner, S., Wang, L., Siu, L.L.

Volltext

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors von Chen, T.W., Razak, A.R., Bedard, P.L., Siu, L.L., Hansen, A.R.

Volltext

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III... von Rothenberg, M.L., Cox, J.V., Butts, C., Navarro, M., Bang, Y.-J., Goel, R., Gollins, S., Siu, L.L., Laguerre, S., Cunningham, D.

Volltext

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC) von Spreafico, A, Oza, A.M, Clarke, B.A, Mackay, H.J, Shaw, P, Butler, M, Dhani, N.C, Lheureux, S, Wilson, M.K, Welch, S, Zhang, T, Yu, C, Stockley, T, Siu, L.L, Kamel-Reid, S, Bedard, P.L

Volltext

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients von Rodriguez-Freixinos, V., Lheureux, S., Mandilaras, V., Clarke, B., Dhani, N.C., Mackay, H., Butler, M.O., Wang, L., Siu, L.L., Kamel-Reid, S., Stockley, T., Bedard, P.L., Oza, A.M.

Volltext

237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncology von Bugano, D, Hess, K, Siu, L.L, Meric-Bernstam, F, Razak, A.R.A, Hong, D.S

Volltext

Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma... von Loong, H.H, Winquist, E, Waldron, J, Chen, E.X, Kim, J, Palma, D, Read, N, Razak, A.R.A, Diaz-Padilla, I, Chan, K, Bayley, A, Hossain, M, Wang, L, Chin, S, Siu, L.L, Hope, A

Volltext

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review von Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L.L., Hansen, A.R.

Volltext

87INCARDIAC TOXICITY OF NOVEL AGENTS von Siu, L.L.

Volltext

Cardiac Toxicity of Novel Agents von Siu, L.L.

Volltext

2863 A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer von Oosting, S.F, Chen, T.W.W, Huang, S.H.H, Wang, L, Waldron, J, Gilbert, R, Goldstein, D.P, Halmos, G.B, Witjes, M.J.H, Gietema, J.A, O'Sullivan, B, Langendijk, J.A, Siu, L.L, Hansen, A.R

Volltext

How liquid biopsies can change clinical practice in oncology von Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., Papadopoulos, N., Kopetz, S., Corcoran, R.B., Siu, L.L., Bardelli, A.

Volltext

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 von O'Neil, B.H, Wallmark, J, Lorente, D, Elez, E, Raimbourg, J, Gomez-Roca, C, Ejadi, S, Piha-Paul, S.A, Moss, R.A, Siu, L.L, Dotti, K, Santoro, A, Gould, M, Yuan, S.S, Koshiji, M, Han, S.W

Volltext

508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041) von Chiu, J.W, Hotte, S.J, Kollmannsberger, C.K, Renouf, D.J, Cescon, D.W, Hedley, D, Chow, S, Moscow, J, Perry, M, Diaz-Padilla, I, Tan, D, Hirte, H, McWhirter, E, Chen, H, Siu, L.L, Bedard, P.L

Volltext

29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors von Lassen, U, Schellens, J.H.M, Siu, L.L, Jonker, D.J, Sorensen, M, Jarutat, T, Wang, K, Geho, D, DeMario, M, Goss, G

Volltext

396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors von de Jonge, M, Sahebjam, S, Mathijssen, R.H, Razak, A, van der Biessen, D, Pronk, L.C, Schnell, D, Siu, L.L

Volltext

OC-018: De-Intensification Candidate Subgroups in HPV(+) Oropharyngeal Cancer Based on Minimal Risk of Distant Metastasis von O'Sullivan, B, Huang, S.H, Siu, L.L, Waldron, J, Zhao, H, Perez-Ordonez, B, Weinreb, I, Irish, J, Liu, F.F, Xu, W

Volltext

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary von Yates, L.R., Seoane, J., Le Tourneau, C., Siu, L.L., Marais, R., Michiels, S., Soria, J.C., Campbell, P., Normanno, N., Scarpa, A., Reis-Filho, J.S., Rodon, J., Swanton, C., Andre, F.

Volltext